The mission of Fusion Genomics is to develop highly sensitive and massively multiplex DNA sequencing based diagnostics. These will expedite diagnosis and genotype-targeted treatments preventing unnecessary deaths and disease resistance for both the individual and the population.

Current molecular diagnostics for infectious diseases can only tests for limited number of pathogens at a time. Therefore, are time-consuming, labor-intensive, and not economically scalable. These limitations are shared by all current tests regardless of the underlying technology, e.g. PCR or array chips.

Fusion Genomics' ONETest system allows one to test and genotype hundreds of pathogens at high specificity in a single test. Our patent pending DNA/RNA capture technology called Quantum Probes when used with next generation DNA sequencing (Illumina/Life) offers best in class specificity and sensitivity than any test currently on the market. Fusion Cloud our online data analytics and management solution, further allows the customer to rapidly analyze, use and share the data as well as augment results with other information such as geo-tags.

We have already proven the effectiveness and applicability of our platform by developing a highly sensitive Influenza genotyping assay. Data from a recently concluded clinical trial, showed that the assay is able to detect and genotype influenza at titres up to 1000X less than comparable PCR assays. A specially modified form of the assay was able to detect and genotype avian influenza from lake bed sediments in wild bird habitats - a first for environmental DNA. We are using our platform to develop a number of other tests including Hepatitis C, MDR/XDR Tuberculosis, HPV, etc.

Fusion’s go-to-market strategy is to partner with large scale, industry leading diagnosis laboratories and leverage the connection to access clinical cases/specimens, resources and a high level of market visibility and influence. Currently, we are working with the BC Centre for Disease Control on Influenza (both human and avian) genotyping and Hepatitis C assays. In addition, we are forming a consortium with the Royal Tropical Institute, Netherlands, The London School of Hygiene and Tropical Medicine and the Ifakara Health Institute, Tanzania to develop tests for Resistant Tuberculosis and Hemorrhagic Fevers. Fusion is also in talks to take our tests through Health Canada and CE approvals (followed by FDA).